Thus, when the specimens of primary lesions are not available in patients with advanced lung adenocarcinoma, the EGFR mutation status of metastatic lesions can be analyzed to represent the primary lesions for guiding the treatment. The gene discussed is EGFR; the disease is lung adenocarcinoma.